Single-domain antibodies for brain targeting

Katerina Lalatsa, Diana Moreira Leite

Research output: Contribution to journalArticlepeer-review

182 Downloads (Pure)


Smaller recombinant antibody fragments as single-domain antibodies (sdAbs) are emerging as credible alternatives because of their target specificity, high affinity, and cost-effective recombinant production. sdAbs have been forged into multivalent and multispecif ic therapeutics, or targeting moieties, that are able to shuttle their linked therapeutic cargo (i.e., drugs, nanoparticles, toxins, enzymes, and radionuclides) to the receptor of interest. Their ability to permeate across the blood brain barrier is receiving industrial interest for neurological and neurooncological indications.
Original languageEnglish
Pages (from-to)20-26
JournalBiopharm International
Issue number8
Publication statusPublished - Aug 2014


Dive into the research topics of 'Single-domain antibodies for brain targeting'. Together they form a unique fingerprint.

Cite this